Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CMV-MVA Triplex
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : City of Hope
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Helocyte gains patent rights to use CMV-MVA Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus-specific, Anti-HIV CAR T Cells for the treatment of adults living with HIV.
Brand Name : CMV-MVA Triplex
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 16, 2023
Lead Product(s) : CMV-MVA Triplex
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : City of Hope
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : CMV-MVA Triplex Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : National Cancer Institute
Deal Size : $3.2 million
Deal Type : Funding
Details : The funding will be used for clinical studies of Triplex, a cytomegalovirus (CMV), universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara viral vector vaccine, being developed by Helocyte and City of Hope.
Brand Name : Triplex
Molecule Type : Vaccine
Upfront Cash : Undisclosed
June 15, 2023
Lead Product(s) : CMV-MVA Triplex Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : National Cancer Institute
Deal Size : $3.2 million
Deal Type : Funding
Lead Product(s) : CMV-modified Vaccinia Ankara Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : $20.0 million
Deal Type : Funding
Details : Triplex is a universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara viral vector vaccine engineered to induce a robust and durable CMV-specific T cell response to three immuno-dominant proteins.
Brand Name : Triplex
Molecule Type : Vaccine
Upfront Cash : Undisclosed
August 11, 2022
Lead Product(s) : CMV-modified Vaccinia Ankara Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : $20.0 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?